Depression or cancer: The choice between serotonin or melatonin?

Medical Hypotheses

Volumn 50, Issue 5, 1998, Pages 385-387

  Panzer, A ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

MELATONIN; SEROTONIN;

ARTICLE; DEPRESSION; HUMAN; HYPOTHESIS; MALIGNANT NEOPLASTIC DISEASE; MONOAMINE METABOLISM; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; STRESS;

EID: 0031745969     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(98)90209-2     Document Type: Article

References (17)

1. Cohen S, Herbert T B. Health psychology: psychological factors and physical disease from the perspective of human psychoneuroimmunology [Review]. Annu Rev Psychol 1996; 47: 113-142.
2. Petroianu A, Chaves D N, De Oliveira O Jr. Comparative incidence of allergy in the presence or absence of cancer. J Int Med Res 1995; 23(5): 358-363.
3. van der Ploeg H M, Kleijn W C, Mook J, van Donge M, Pieters A M, Leer J W. Rationality and antiemotionality as a risk factor for cancer: concept differentiation. J Psychosom Res 1989; 33(2): 217-225.
4. Reiter R J. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocrine Rev 1991; 12(2): 151-180.
5. Young I M, Leone R M, Francis P, Stovell P, Silman R E. Melatonin is metabolized to N-acetyl serotonin and 6-hydroxymelatonin in man. J Clin Endocrinol Metab 1985; 60(1): 114-119.
6. Baldwin D, Rudge S. The role of serotonin in depression and anxiety [Review]. Int Clin Psychopharmacol 1995; 9(Suppl 4): 41-45.
7. Wong D T, Bymaster F P. Development of antidepressant drugs: fluoxetine (Prozac) and other selective serotonin uptake inhibitors [Review]. Adv Exp Med Biol 1995; 363: 77-95.
8. Lissoni P, Barni S, Fossati V et al. A randomized study of neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin compared to supportive care alone in patients with untreatable metastatic solid tumour. Support Care Cancer 1995; 3(3): 194-197.
9. Lissoni P, Meregalli S, Fossati V et al. A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer. Tumori 1994; 80(6): 464-67.
10. Lissoni P, Meregalli S, Nosetto L et al. Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. Oncology 1996; 53: 43-46.
11. Lissoni P, Ardizzoia A, Barni S et al. A randomized study of tamoxifen alone versus tamoxifen plus melatonin in estrogen receptor-negative heavily pretreated metastatic breast cancer patients. Oncology Reports 1995; 2: 871-873.
12. Dinan T G. Noradrenergic and serotonergic abnormalities in depression: stress-induced dysfunction? [Review]. J Clin Psychiatry 1996; 57(Suppl 4): 14-18.
13. Kennedy S H, Brown G M. Effect of chronic antidepressant treatment with adinazolam and desipramine on melatonin output. Psychiatry Res 1992; 43(2): 177-185.
14. Hilakivi-Clarke L, Rowland J, Clarke R, Lippman M E. Psychosocial factors in the development and progression of breast cancer [Review]. Breast Cancer Res Treat 1994; 29(2): 141-160.
15. Temoshok L. Personality, coping style, emotion and cancer: towards an integrative model [Review]. Cancer Surv 1987; 6(3): 545-567.
16. Bartsch C, Bartsch H, Jain A K, Laumas K R, Wetterberg L. Urinary melatonin levels in human breast cancer patients. J Neural Transm Suppl 1981; 52(4): 281-294.
17. Bartsch C, Bartsch H, Maestroni G J M. Conti A, Reiter R J, eds. Melatonin secretion in oncological patients: current results and methodological considerations. In: Advances in Pineal Research. London: John Libbey, 1994: 283-301.